Objective: The human Rho guanine nucleotide exchange factor 11 (ARHGEF11) gene is one of the candidate genes for type 2 diabetes mellitus (T2DM). ARHGEF11 is mapped to chromosome 1q21, which has susceptible risk loci for T2DM and schizophrenia. We hypothesized that ARHGEF11 contributes to the pathogenesis of schizophrenia.
Introduction
It is well established that patients with schizophrenia are at increased risk for the development of type 2 diabetes mellitus (T2DM) (Bushe and Holt, 2004; Suvisaari et al., 2008) . Epidemiological surveys show that the prevalence of T2DM in patients with schizophrenia is approximately 6% to 21%, two to three times higher than in the general population (Bushe and Holt, 2004; Suvisaari et al., 2008) . Some studies have suggested that the medication used to treat schizophrenia may contribute to the risk of diabetes (Scheen and De Hert, 2007; Tschoner et al., 2007) . However, apart from adverse effects related to medication, recent studies show an elevated risk of T2DM among drug-naïve or first-episode patients with schizophrenia and their relatives (Ryan et al., 2003 , Spelman et al., 2007 Guest et al., 2010) . Thus, T2DM and schizophrenia are common diseases that seem to share a complex mode of inheritance that includes both genetic factors and environmental determinants (Gough and O'Donovan, 2005) .
Previous genetic studies show that T2DM and schizophrenia have a number of overlapping risk loci, including chromosomes 1p13, 1p36, 1q21-24, 1q25, 2q14, 2q33, 2q36, 3p22, 3q29, 4q25, 5q13, 6p21, 6q25, 7p15, 7p21, 7q21, 7q31, and 9p24 (Lin and Shuldiner, 2010) . Chromosome 1q21 was reported to have a linkage to T2DM by several previous studies (Vionnet et al., 2000; Das and Elbein, 2007) . This location has also been implicated as a schizophrenia susceptibility locus (Brzustowicz et al., 2000; Craddock et al., 2005) .
The human Rho guanine nucleotide exchange factor 11 (ARHGEF11) gene is located in chromosome 1q21, and ARHGEF11 variants have been associated with T2DM in multiple ethnic populations Ma et al., 2007; Böttcher et al., 2008; Jin et al., 2010; Liu et al., 2011) .
ARHGEF11 is expressed in the pancreas, liver, adipose tissue (Fukuhara et al., 1999) , and multiple brain regions (Huerta et al., 2006) . It mediates interaction with the actin cytoskeleton (Banerjee and Wedegaertner; and activates RhoA GTPases that belong to small GTP-binding proteins of Rho families (Fukuhara et al., 1999; Rümenapp et al., 1999) .
Rho GTPases play fundamental roles in the regulation of G protein signaling and a number of cellular processes, including insulin secretion (Hirosumi et al., 2002) , insulin signaling (Kowluru and Veluthakal, 2005) , and lipid metabolism (Houssa et al., 1999) . Rho GTPases are also implicated in the regulation of neuronal morphogenesis, including migration, polarity, axon growth, axon guidance, dendrite elaboration, dendrite plasticity, and synapse formation (Luo, 2000) .
In a yeast two-hybrid screen, ARHGEF11 directly interacted with disrupted-in-schizophrenia 1 (DISC1), which is one of the candidate genes for schizophrenia (Millar et al., 2003) . DISC1 modulates the structure and function of the spines of the glutamate synapse via another member of the RhoGEF family, KALRN (Hayashi-Takagi et 5 al., 2010) .
We hypothesized that ARHGEF11 contributes to the pathogenesis of schizophrenia.
Therefore, we examined the association between patients with schizophrenia and ARHGEF11.
Methods

Subjects
The subjects of this association study comprised 490 unrelated patients fulfilling the ICD-10 (International Classification of Disease, Version 10, WHO 1992) diagnostic criteria for schizophrenia (250 males and 240 females, average age ± standard deviation (S.D.), 50.5 ± 12.8 years; 223 were diagnosed with the paranoid subtype, 241 with the hebephrenic subtype, 18 with the catatonic subtype, and 8 with the undifferentiated subtype), and 500 age-, sex-, and geographical origin-matched control subjects (250 males and 250 females, average age ± S.D., 51.0 ± 14.5 years). Diagnosis of schizophrenia and determination of subtype were performed by two trained psychiatrists on the basis of all available information and unstructured interviews. We excluded the catatonic subtype due to the low sample size and the undifferentiated subtype due to its heterogeneity. Controls were recruited primarily from medical staff members. Psychiatrically, medically, and neurologically healthy controls were 6 evaluated using unstructured interviews to exclude individuals who had current or past contact with psychiatric services. All subjects were Japanese. This study was approved by the Ethics Committee of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. Written informed consent was obtained from all participants.
Genotyping
Peripheral blood was obtained from the subjects, and genomic DNA was extracted from peripheral leukocytes using a standard procedure. We selected eight single nucleotide polymorphisms (SNPs), rs822585, rs6427340, rs6427339, rs1006168, rs12136088, rs2275199 (N1207N), rs868188 (S1456G), and rs945508 (R1467H), of ARHGEF11 for genetic association analyses (see Fig. 1 ). These eight SNPs have shown significant associations with T2DM Ma et al., 2007; Böttcher et al., 2008; Jin et al., 2010; Liu et al., 2011) . The concentration and purity of DNA samples was assessed using a NanoDrop 1000 spectrophotometer (Thermo Scientific, USA). The concentration of DNA samples was adjusted to 20 ng/μl. The purity was estimated from the ratio of the absorbance values measured at wavelengths of 260 nm and 280 nm (defined as a 260/280 ratio between 1.8 and 2.0). Eight SNPs (rs822585, rs6427340, rs6427339, rs1006168, rs12136088, rs2275199, rs868188, and rs945508) Furthermore, we performed a post hoc power calculation using a G* power program (Faul et al., 2007) . We found that the sample size had >0.90 power for detecting a significant association (alpha level <0.05) when an effect size index of 0.2 was used.
In silico analysis of SNP functions
To investigate the functions of non- of 0.97). We then analyzed two-and three-loci haplotypes in block 1, and two-loci haplotypes in block 2 of patients with schizophrenia and controls. We found significant differences in the frequencies of rs6427340-rs6427339 and rs822585-rs6427340-rs6427339
haplotypes of ARHGEF11 in block 1 (global permutation P=0.00047 and 0.0032, respectively).
The frequencies of C-C of rs6427340-rs6427339 and A-C-C of rs822585-rs6427340-rs6427339 in schizophrenia were higher (permutation P=0.0010 and 0.0018, respectively) than in controls, indicating a higher risk for schizophrenia. The frequencies of A-C-T of rs822585-rs6427340-rs6427339 in schizophrenia were lower (permutation P=0.031) than in controls, indicating a possible protective effect (see Table 3 ).
After stratification by subtype of schizophrenia, we found significant differences in the frequencies of the rs6427340-rs6427339 and rs822585-rs6427340-rs6427339 haplotypes between the paranoid subtype and controls (global permutation P=0.0018 and 0.0077, respectively) and between the hebephrenic subtype and controls (global permutation P=0.00007 and 0.00025, respectively). The frequencies of C-C of rs6427340-rs6427339 and A-C-C of rs822585-rs6427340-rs6427339 in the hebephrenic subtype (permutation P=0.00005 and 0.000083, respectively) were higher than in controls, indicating a higher risk for schizophrenia. The frequency of C-T of rs6427340-rs6427339 in the paranoid subtype (permutation P=0.016) was lower than in controls, indicating a possible protective effect (see Table 3 ).
3.3. In silico analysis of SNP functions Rs868188 (S1456G) had a predicted sequence conservation score of 0.012 and was predicted to be "benign". Rs945508 (R1467H) had a predicted sequence conservation score of 0.168 and was predicted to be "possibly damaging".
Discussion
To the best of our knowledge, this is the first genetic association study of ARHGEF11 in patients with schizophrenia. Though we did not find allelic and genotypic associations with schizophrenia, analysis of the haplotype combinations provided significant evidence for an association with schizophrenia. It was reported that having the A allele of rs822585, C allele of rs6427340, or T allele of rs6427339 was associated with T2DM in an Amish population . In our study, the frequency of A-C-T of rs822585-rs6427340-rs6427339 was significantly higher in controls than in patients with schizophrenia. This result contradicts the view that liability to T2DM is associated with vulnerability to schizophrenia. In the dbSNP database of the NCBI Web Server (http://www.ncbi.nlm.nih.gov/projects/SNP), the T allele of rs822585, T allele of rs6427340, and C allele of rs6427339 were estimated to be minor alleles in a Japanese population (each allele frequency was 20%, 24%, and 24%, respectively). This data is consistent with our results, and different from that reported for an Amish population.
A possible explanation for this incongruity may be the difference in ethnic backgrounds.
In several other individual haplotypes, the frequencies of C-C of rs6427340-rs6427339
and A-C-C of rs822585-rs6427340-rs6427339 were associated with higher risks for schizophrenia. These haplotypes were also strongly associated with the hebephrenic subtype after stratification by subtype of schizophrenia. However, these differences may be mainly due to the low frequencies of rare haplotypes in the controls (haplotype frequency was 0.004).
Minor A allele carriers (GA + AA genotype) of rs945508 (R1467H) were reported to have markedly higher risk of T2DM, higher body mass index, higher serum fasting plasma glucose, higher fasting insulin, and higher homeostasis model assessment of insulin resistance values (Liu et al., 2011) . G allele carriers (GA＋GG genotype) of rs868188 (S1456G) were reported to have a higher incidence of T2DM . Rs868188 (S1456G) and rs945508 (R1467H) are non-synonymous SNPs that result in an amino acid substitution. In silico analysis predicted rs868188 (S1456G) to be "benign", most likely having no phenotypic effect. Rs945508 (R1467H) was predicted to be "possibly damaging", in that it may affect the protein function and/or structure of ARHGEF11. Although we did not find significant allelic or genotypic associations or minor allele carrier frequencies, the allele frequencies of rs822585, rs6427340, rs6427339, and rs868188 (S1456G) (P=0.031, 0.036, 0.023, and 13 0.020, respectively) and minor allele carrier frequencies of rs945508 (R1467H) (P=0.046) of ARHGEF11 showed marginally significant associations (P<0.05) between the paranoid subtype of schizophrenia and controls. Because our sample size was small after stratification by subtype of schizophrenia, we may need to confirm whether these results are only marginal or not using a larger sample.
It is reported that the expression levels of ARHGEF11 mRNA were higher in the postmortem thalamus of patients with schizophrenia than of controls (Davidkova et al., 2003) .
Although the function of ARHGEF11 mRNA overexpressed in the thalamus is unclear, the thalamus provides a nodal link for multiple functional circuits, and schizophrenia-associated abnormalities in thalamic expression of genes could reflect aberrations in extrathalamic components of these circuits (Byne et al., 2009) . Furthermore, it is reported that abnormalities in the thalamus may relate to hallucinations in patients with schizophrenia (Martínez-Granados et al., 2008) . ARHGEF11 may be associated with the function of the thalamus and related to positive symptoms in patients with schizophrenia.
Several points should be considered in the present study. The first is that the selection of the eight SNPs not based on a Tagger selection program such as Haploview.
Therefore, further analysis of the remaning SNPs is needed to confirm that ARHGEF11 is associated with schizophrenia. The second is that we subcategorized the subjects with schizophrenia according to ICD-10 criteria because the schizophrenia subtypes appear to be 14 more homogeneous than the broader disorder (Mirnics and Lewis, 2001 ). However, the subtype categories of schizophrenia were eliminated from the Diagnostic and Statistical
Manual of Mental Disorders-5 due to their limited diagnostic stability, low reliability, and poor validity. Therefore, it might be useless to dichotomize the paranoid and hebephrenic subtypes. The third is that we considered P values <0.05 or 0.016 as statistically significant, and therefore found significant associations. The P value for a significance threshold may be 0.0062 (0.05/8) or 0.0020 (0.05/8X3) instead of 0.05 or 0.016 if multiple allelic frequencies and genotypic distribution (8SNPs) are considered. Although significant differences might be eliminated after correction for multiple testing, we found significant associations with schizophrenia in several haplotype combinations.
In conclusion, these findings indicated that ARHGEF11 may affect the susceptibility to schizophrenia in a Japanese population. Further replication studies in distinct populations and larger sample are necessary to confirm the association between ARHGEF11 and schizophrenia.
15 We define significant LD if D' and r 2 are greater than 0.8.
Rs822585, rs6427340, and rs6427339 constitute one block (block 1), and rs1006168 and rs12136088 constitute another block (block 2). 
